.jpg)
The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the first and only treatment approved for this rare autoimmune disease in the United States. An estimated 200,000 people in the United States are living with IgG4-RD...
Copyright © 2023 vipnews. All Rights Reserved
